Our verdict is Likely benign. Variant got -6 ACMG points: 2P and 8B. PM2BP6_Very_Strong
The NM_000368.5(TSC1):c.213C>A(p.His71Gln) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000124 in 1,614,038 control chromosomes in the GnomAD database, with no homozygous occurrence. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely benign (★★).
TSC1 (HGNC:12362): (TSC complex subunit 1) This gene is a tumor suppressor gene that encodes the growth inhibitory protein hamartin. The encoded protein interacts with and stabilizes the GTPase activating protein tuberin. This hamartin-tuberin complex negatively regulates mammalian target of rapamycin complex 1 (mTORC1) signaling which is a major regulator of anabolic cell growth. This protein also functions as a co-chaperone for Hsp90 that inhibits its ATPase activity. This protein functions as a facilitator of Hsp90-mediated folding of kinase and non-kinase clients, including TSC2 and thereby preventing their ubiquitination and proteasomal degradation. Mutations in this gene have been associated with tuberous sclerosis and lymphangioleiomyomatosis. [provided by RefSeq, May 2022]
Verdict is Likely_benign. Variant got -6 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP6
Variant 9-132925737-G-T is Benign according to our data. Variant chr9-132925737-G-T is described in ClinVar as [Likely_benign]. Clinvar id is 466065.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr9-132925737-G-T is described in Lovd as [Likely_benign].
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Jan 26, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Aug 12, 2024
Myriad Genetics, Inc.
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
This variant is considered likely benign. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. -
Hereditary cancer-predisposing syndrome Benign:1
Oct 21, 2022
Ambry Genetics
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);Loss of catalytic residue at L73 (P = 0.0823);